Chronic Hepatitis C Virus Management: 2000

Abstract

Spanish

French

Objective:

To review recent advances that have significantly changed the management of chronic hepatitis C virus (HCV) infection.

Data Sources:

A MEDLINE search (2000–July 2005) was conducted using key words such as hepatitis C, interferon, pegylated interferon, and therapy.

Study Selection and Data Extraction:

All articles pertaining to treatment of chronic HCV infection were identified. Studies evaluating HCV treatment in treatment-naive patients were considered for this review.

Data Synthesis:

Over the past several years, response to treatment for chronic HCV infection has significantly improved with the use of pegylated interferon and ribavirin therapy. Treatment response is influenced by HCV genotype and viral load, as well as patient-related factors, Including adherence.

Conclusions:

Treatment of chronic HCV infection has improved, with overall response rates of approximately 55%. Identification and management of common adverse effects is important in maximizing adherence and response to therapy. Studies are needed to further delineate the optimum treatment of chronic HCV infection in specific patient populations.

Keywords

antiviral therapy hepatitis C interferon pegylated interferon ribavirin

Get full access to this article

View all access options for this article.

References

Yen

, Keeffe

, Ahmed

The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003;36:47-53. DOI 10.1097/00004836-200301000-00015

Herrine

. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002;136:747-57.

Hoofnagle

. Course and outcome of hepatitis C. Hepatology 2002;36(5 suppl 1):S21-9. DOI 10.1053/jhep.2002.36227

Seeff

. Natural history of chronic hepatitis C. Hepatology 2002;36(5 suppl 1):S35-46. DOI 10.1053/jhep.2002.36806

Kim

. The burden of hepatitis C in the United States. Hepatology 2002;36(5 suppl 1):S30-4. DOI 10.1053/jhep.2002.36791

National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002—June 10–12, 2002. Hepatology 2002;36(5 suppl 1):S3-20. DOI 10.1053/jhep.2002.37117

Sherman

, Bain

, Villeneuve

. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol 2004;18:715-28.

Strader

, Wright

, Thomas

, Seeff

. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. DOI 10.1002/hep.20119

McHutchison

, Gordon

, Schiff

. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92. DOI 10.1056/NEJM199811193392101

10.

Poynard

, Marcellin

, Lee

. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32. DOI 10.1016/S0140-3736 (98)07124-4

11.

Reichard

, Norkrans

, Fryden

, Braconier

, Sonnerborg

, Weiland

Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7. DOI 10.1016/S0140-6736 (97) 06088-1

12.

Luxon

, Grace

, Brassard

, Bordens

Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002;24:1363-83. DOI 10.1016/S0149-2918(02)80042-x

13.

Medina

, Garcia-Buey

, Moreno-Monteagudo

, Trapero-Marugan

, Moreno-Otero

Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003;60:135-43. DOI 10.1016/j.antiviral.2003.08.009

14.

Zeuzem

, Welsch

, Herrmann

Pharmacokinetics of peginterferons. Semin Liver Dis 2003;23(suppl 1):23-8. DOI 10.1055/s-2003-41631

15.

Product monograph. Peginterferon alfa-2b. Kenilsworth, NJ: Schering-Plough, 2005. www.spfiles.com/pipeg-intron.pdf (accessed 2005 Jul 8).

16.

Heathcote

, Shiftman

, Cooksley

. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80. DOI 10.1056/NEJM200012073432302

17.

Reddy

, Wright

, Pockros

. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8. DOI 10.1053/jehp.2001.21747

18.

Zeuzem

, Feinman

, Rasenack

. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72. DOI 10.1056/NEJM200012073432301

19.

Lindsay

, Trepo

, Heintges

. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403. DOI 10.1053/jhep.2001.26371

20.

Poynard

, Yuen

, Ratziu

, Lai

. Viral hepatitis C. Lancet 2003;362:2095-100. DOI 10.1016/S0140-6736(03)15109-4

21.

Flamm

. Chronic hepatitis C virus infection. JAMA 2003;289:2413-7. DOI 10.10011jama.289.18.2413

22.

Craxi

, Licata

Clinical trial results of peginterferons in combination with ribavirin. Sem Liver Dis 2003;23(suppl 1):35-46. DOI 10.1055/S-2003-41633

23.

Zeuzem

Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?

Ann Intern Med 2004;140:370-81.

24.

Abdo

, Lee

. Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol 2004;19:1233-9. DOI 10.111/j.1440-1746.2003.03325.x

25.

Manns

, McHutchison

, Gordon

. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65. DOI 10.1016/S0140-6736(01)06102.5

26.

Fried

, Shiftman

, Reddy

. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. DOI 10.10567NEJMoa020047

27.

Davis

, Wong

, McHutchison

, Manns

, Harvey

, Albrecht

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52. DOI 10.1053/jhep.2003.50364

28.

Poynard

, McHutchison

, Goodman

, Ling

, Albrecht

Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31:211-8. DOI 10.1002/hep.510310131

29.

Zeuzem

, Hultcrantz

, Bourliere

. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9. DOI 10.1016/S0168-8278(04)00060-l

30.

Hadziyannis

, Sette

, Morgan

. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.

31.

Dalgard

, Bjoro

, Helium

. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5. DOI 10.1002/hep.20467

32.

Mangia

, Santaro

, Minerva

. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17. DOI 10.1056/NEJMoa042608

33.

Manns

. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am 2004;33:S11-24. DOI 10.10167j.gtc.2003.12.003

34.

McHutchison

, Manns

, Patel

. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9. DOI 10.1053/gast.2002.35950

35.

Diagno

, Hassanein

, Rodes

, Ackrill

, Sedarati

Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-α2a and ribavirin (letter). Ann Intern Med 2004;140:72-3.

36.

Hasan

, Asker

, Al-Khaldi

. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7. DOI 10.1111/j.1572-0241.2004.40077.x

37.

Khuroo

, Khuroo

, Dahab

. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004;20:931-8. DOI 10.1111/j.1365-2036.2004.02208.x

38.

Esmat

, Abouzied

, Adel-Aziz

, Strickland

Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin (abstract). Hepatology 2003;38:324A. DOI 10.10167S0270-9139(03)80367-1

39.

Shobokshi

, Serebour

, Skakni

, Al Khalifa

Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia (abstract). Hepatology 2003;38:996A. DOI 10.10167S0270-9139(03)81034-0

40.

Thakeb

FAI

, Omar

, El Awady

, Isshak

. Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients (abstract). Hepatology 2003;38:278A. DOI 10.1016/S0270-9139(03)80295-1

41.

Alfaleh

, Hadad

, Khuroo

. Peginterferon α-2b plus ribavirin compared to interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004;24:568-74. DOI 10.1111/j.1478-3231.2004.0976.x

42.

Kamal

, EL Tawil

, Nakano

. Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype4: impact of treatment duration and viral kinetics on sustained virologic response. Gut 2005;54:858-66. DOI 10.11367gut.2004.057182

43.

Reddy

, Hoofnagle

, Tong

. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787-93. DOI 10.1002/hep.510300319

44.

Kinzie

, Naylor

, Nathani

. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001;8:264-9. DOI 10.1046/j.1365-2893.2001.00292.x

45.

De Maria

, Colantoni

, Idilman

, Friedlander

, Harig

, Van Thiel

. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002;49:788-92.

46.

McHutchison

, Poynard

, Pianko

. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-23.

47.

Muir

, Bornstein

, Killenberg

. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71. DOI 10.1056/NEJMoa032502

48.

Russo

, Fried

. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9. DOI 10.10167S0016-5085(03)00394-9

49.

Fried

. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 suppl 1):S237-44. DOI 10.1053/jhep.2002.36810

50.

Aspinall

, Pockros

. Review article: the management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther 2004;20:917-29. DOI 10.1111/j.1365-2036.2004.02192.x

51.

Levenson

, Fallon

. Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 1993;88:760-1.

52.

Gleason

, Yates

. Five cases of interferon-alpha–induced depression treated with antidepressant therapy. Psychosomatics 1999;40:510-2.

53.

Schramm

, Lawford

, Macdonald

, Cooksley

WGE

. Sertraline treatment of interferon-alfa–induced depressive disorder. Med J Aust 2000;173:359-61.

54.

Kraus

, Schafer

, Faller

, Csef

, Scheurlen

Paroxetine for the treatment of interferon-α–induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9. DOI 10.10467j.1365-2036.2002.01265.x

55.

Farah

Interferon-induced depression treated with citalopram (letter). J Clin Psychiatry 2002;63:166-7.

56.

Hauser

Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN α–induced depression. Gastroenterol Clin North Am 2004;33(1 suppl):S37-50. DOI 10.1016/j.gtc.2003.12.005

57.

Schaefer

, Schwaiger

, Garkisch

. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:793-8. DOI 10.1016/j.jhep.2005.01.020

58.

Garcia-Pando

, Garcia del Pozo

, Shancez

, Martin

, Rueda de Castro

, Lucena

. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002;63:135-7.

59.

Malek-Ahmadi

, Ghandour

Bupropion for treatment of interferon-induced depression. Ann Pharmacother 2004;38:1202-5. DOI 10.1345/aph.1D516

60.

Sulkowski

. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003;37(suppl 4):S315-22. DOI 10.1086/376911

61.

Dieterich

, Wasserman

, Brau

. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.

62.

Afdhal

, Dieterich

, Pockros

. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11. DOI 10.1053/j.gastro.2004.01.027

63.

Pockros

, Shiffman

, Schiff

. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8. DOI 10.1002/hep.20482

64.

Gonzalez

, Jacobson

. The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation. Cleve Clin J Med 2004;71(suppl 3):S22-6.

Chronic Hepatitis C Virus Management: 2000–2005 Update

Abstract

Objective:

Data Sources:

Study Selection and Data Extraction:

Data Synthesis:

Conclusions:

Keywords

Get full access to this article

References